Drug Stocks' Earnings Slated for This Week: RDY, AVXS, ESALY
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:03AM CDT
Quite a few companies are still yet to report results. Let's take a peek at a few drug stocks that will report quarterly results later this week
JNJ: 116.99 (+1.19), GILD: 85.89 (-1.53), PFE: 35.43 (+0.18), AMGN: 156.73 (-1.27), ABBV: 60.60 (-1.13), RDY: 45.81 (-1.06), AVXS: 44.99 (+1.34), NVS: 80.56 (-0.83)
Jazz (JAZZ) Q1 Earnings: A Beat in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Fri May 06, 4:13PM CDT
Jazz Pharmaceuticals (JAZZ), which is set to report first-quarter 2016 results on May 10, delivered a positive earnings surprise of 36.75% last quarter.
IPXL: 33.38 (-0.28), CLSN: 1.42 (+0.01), JAZZ: 155.51 (+0.55)
Corcept's (CORT) Q4 Earnings Impress, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 10:00AM CST
Corcept Therapeutics Incorporated (CORT) reported earnings of 1 cent per share in the fourth quarter of 2015, while Zacks Consensus Estimates was a loss of 2 cents
PETX: 7.11 (-0.29), TRIL: 9.98 (-0.71), CORT: 5.37 (-0.27)
Halozyme Raises Funds to Support Ongoing Oncology Studies
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 3:55PM CST
Halozyme (HALO) announced that it has entered into a $150 million credit agreement secured by future royalties from Enhanze products, which Halozyme is entitled to receive from its collaborations with Roche and Baxalta, Inc.
HALO: 8.98 (-0.23), BXLT: 46.02 (-0.18)
Arena (ARNA)/Eisai's Belviq XR NDA Accepted for Review
Arpita Dutt - Zacks Investment Research - Tue Dec 01, 3:32PM CST
Arena (ARNA) is looking to get a once-daily formulation of its chronic weight management treatment approved in the U.S.
ACHN: 9.82 (+0.21), BXLT: 46.02 (-0.18), ARNA: 2.11 (-0.04)
Arena 3Q Loss Narrower-Than-Expected, Belviq in Focus
Arpita Dutt - Zacks Investment Research - Wed Nov 11, 9:34AM CST
Arena (ARNA) is looking to cut costs and improve efficiency through a restructuring plan.
ACHN: 9.82 (+0.21), BXLT: 46.02 (-0.18), ARNA: 2.11 (-0.04)
Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
Jazz Pharmaceuticals (JAZZ) reported third-quarter 2015 adjusted earnings of $2.16 per share, up 7.5% year over year.
JAZZ: 155.51 (+0.55), TEVA: 53.44 (-0.55), CNCE: 13.05 (-0.25)
Corcept's Q2 Loss Narrower than Expected, View Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 10:35AM CDT
Corcept Therapeutics (CORT) posted loss of a penny per share in the second quarter of 2015, narrower than both the Zacks Consensus Estimate of a loss of 5 cents.
VRX: 24.88 (+0.96), ANAC: 99.05 (-0.14), CORT: 5.37 (-0.27)
Arena Pharmaceuticals 2Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 06, 8:10AM CDT
Although Arena Pharmaceuticals' (ARNA) second quarter loss was narrower-than-expected, revenues missed expectations.
GILD: 85.89 (-1.53), ARNA: 2.11 (-0.04)
Will Epizyme (EPZM) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 05, 12:40PM CDT
Epizyme (EPZM) has an Earnings ESP of 3.08% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
INO: 11.11 (-0.13), EPZM: 12.40 (-0.59), GSK: 42.06 (-0.45)
Will Arena Pharmaceuticals (ARNA) Surprise Q2 Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 04, 12:00PM CDT
Investor focus will remain on the performance of Arena's (ARNA) obesity treatment - Belviq.
BDSI: 2.89 (-0.03), VVUS: 1.21 (-0.06), ARNA: 2.11 (-0.04)